21323-98-8

Basic information

• Product Name: Benzenepropanoic acid, 4-(1,1-dimethylethoxy)-
• CAS NO: 21323-98-8
• Molecular Formula: C13H18O3
• Molecular Weight: 222.284
• Mol File: 21323-98-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzenepropanoic acid, 4-(1,1-dimethylethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenepropanoic acid, 4-(1,1-dimethylethoxy)-(21323-98-8)
• EPA Substance Registry System: Benzenepropanoic acid, 4-(1,1-dimethylethoxy)-(21323-98-8)

Safety Data

• Hazardous Substances Data: 21323-98-8(Hazardous Substances Data)

Upstream product

• 501-97-3 4-hydroxyphenylpropionic acid 
• 57699-45-3 p-tert-butoxybenzaldehyde 
• 138585-07-6 t-Butyl p-t-butoxyhydrocinnamate 
• 60876-70-2 4-tert-butoxybromobenzene 
• 79-10-7 acrylic acid 
• 155904-35-1 3-(4-tert-butoxy-phenyl)-acrylic acid 

Downstream Products

• 1400684-94-7 3-(4-(tert-butoxy)phenyl)-N-methoxy-N-methylpropanamide 
• 941293-00-1 3-(4-tert-butoxyphenyl)propionaldehyde 
• 1400685-19-9 (E)-benzyl 2-(4-(tert-butoxy)benzyl)but-2-enoate 
• 727716-46-3 3-(4-tert-butoxyphenyl)propionic acid benzyl ester 
• 1165738-62-4 3-(4-tert-butoxyphenyl)-N-(3-fluoro-4-(methylsulfonamido)benzyl)propanamide 
• 397883-78-2 4-(4-benzyl-2-oxo-oxazolidin-3-yl)-3-(4-tert-butoxy-benzyl)-N-(2,4-dimethoxy-benzyl)-N-methyl-4-oxo-butyramide 
• 326473-17-0 (4-S)-4-benzyl-3-[3-(4-tert-butoxyphenyl)-propionyl]-oxazolidin-2-one 
• 397883-85-1 (2S,3S)-2-[(S)-4-Benzyloxycarbonyl-2-((S)-4-benzyloxycarbonyl-2-{(R)-3-[4-(bis-benzyloxy-phosphoryloxy)-phenyl]-2-methylcarbamoylmethyl-propionylamino}-butyrylamino)-butyrylamino]-3-methyl-pentanoic acid benzyl ester 
• 397883-84-0 (2S,3S)-2-[(S)-4-Benzyloxycarbonyl-2-((S)-4-benzyloxycarbonyl-2-{(R)-3-[4-(bis-benzyloxy-phosphoryloxy)-phenyl]-2-dimethylcarbamoylmethyl-propionylamino}-butyrylamino)-butyrylamino]-3-methyl-pentanoic acid benzyl ester 
• 326473-19-2 (2R)-2-(4-tert-butoxybenzyl)-N-(2,4-dimethoxybenzyl)-N-methylsuccinamic acid benzyl ester 
• 397883-83-9 (2R)-2-[4-(bis-benzyloxy-phosphoryloxy)-benzyl]-N-methyl-succinamic acid 
• 397883-82-8 (2R)-2-[4-(bis-benzyloxy-phosphoryloxy)-benzyl]-N,N-dimethyl succinamic acid 
• 397883-76-0 [3R,4S]-4-(4-benzyl-2-oxo-oxazolidin-3-yl)-3-(4-tert-butoxybenzyl)-N,N-dimethyl-4-oxo-butyramide 

Relevant articles and documents

Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids

Matriptase-2, a type II transmembrane serine protease (TTSP), is expressed in the liver and regulates iron homeostasis via the cleavage of hemojuvelin. Matriptase-2 emerges as an attractive target for the treatment of conditions associated with iron overload, such as hemochromatosis or beta-thalassemia. Starting from the crystal structure of its closest homolog matriptase, we constructed a homology model of matriptase-2 in order to further optimize the selectivity of serine trap peptidomimetic inhibitors for matriptase-2 vs matriptase. Careful modifications of the P4, P3 and P2 positions with the help of unnatural amino acids led to a thorough understanding of Structure-Activity Relationship and a >60-fold increase in selectivity for matriptase-2 vs matriptase. Additionally, the introduction of unnatural amino acids led to significant increases in plasma stability. Such compounds represent useful pharmacological tools to test matriptase-2 inhibition in a context of iron overload.

Design, synthesis, and biological evaluation of novel diarylalkyl amides as TRPV1 antagonists

We have developed a new class of diarylalkyl amides as novel TRPV1 antagonists. They exhibited potent 45Ca2+ uptake inhibitions in rat DRG neuron. In particular, the amide 59 was identified as a potent antagonist with IC50 of 57 nM. The synthesis and structure-activity relationship of the diarylalkyl amides are also described.

Use of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide mimics in SH2 antagonists

Novel conformationally constrained phosphotyrosine pseudopeptide derivatives of the tetrapeptide pY-E-E-I were prepared and evaluated as SH2 binding antagonists. (C) 2000 Elsevier Science Ltd.